A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Single and Multiple Doses of GS-9190, a Novel Anti-hepatitis C Virus Drug, in Treatment-naive Subjects with Chronic Hepatitis C Genotype 1 infection

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Single and Multiple Doses of GS-9190, a Novel Anti-hepatitis C Virus Drug, in Treatment-naive Subjects with Chronic Hepatitis C Genotype 1 infection

Suspended
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2010

At a glance

  • Drugs Tegobuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Nov 2007 Interim results were presented at AASLD 2007.
    • 29 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top